866-997-4948(US-Canada Toll Free)

Influenza B Infections - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Therapeutic Area

No. of Pages : 39 Pages


Global Markets Direct’s, \'Influenza B Infections - Pipeline Review, H2 2013\', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Influenza B Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza B Infections. 

Influenza B Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Influenza B Infections.
  • A review of the Influenza B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Influenza B Infections pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Influenza B Infections.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Influenza B Infections pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Introduction
Global Markets Direct Report Coverage
Influenza B Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Influenza B Infections
Influenza B Infections Therapeutics under Development by Companies
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Influenza B Infections Therapeutics – Products under Development by Companies
Companies Involved in Influenza B Infections Therapeutics Development
Inovio Biomedical Corporation
Crucell N.V.
LG Life Sciences, Ltd
LigoCyte Pharmaceuticals, Inc.
Chimerix, Inc.
REPLICor Inc.
Influenza B Infections – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
REP-9-AC - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Influenza VLP vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DtwP-HB-Hib (liq) Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flufirvitide-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INO-3510 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-8071 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CR-8033 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Influenza B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Influenza B Infections Therapeutics – Drug Profile Updates
Influenza B Infections Therapeutics - Dormant Products
Influenza B Infections – Product Development Milestones
Featured News & Press Releases
Oct 18, 2012: Sanofi Pasteur\'s sBLA For New Four-Strain Influenza Vaccine Accepted For Review By FDA
Aug 22, 2012: Biota Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study
Mar 11, 2011: Sanofi Pasteur And Daiichi Sankyo Announce Voluntary Recall Of Hemophilus Influenza Type B Conjugate Vaccine
Oct 26, 2000: Hexavalent pediatric vaccines licensed in EU
Apr 23, 1993: FDA Approval of Use of a New Haemophilus b Conjugate Vaccine and a Combined Diphtheria-Tetanus-Pertussis and Haemophilus b Conjugate Vaccine for Infants and Children

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products Under Development for Influenza B Infections, H1 2013
Products under Development for Influenza B Infections – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Inovio Biomedical Corporation, H1 2013
Crucell N.V., H1 2013
LG Life Sciences, Ltd, H1 2013
LigoCyte Pharmaceuticals, Inc., H1 2013
Chimerix, Inc., H1 2013
REPLICor Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Influenza B Infections Therapeutics – Drug Profile Updates
Influenza B Infections Therapeutics – Dormant Products

List of Chart


Number of Products under Development for Influenza B Infections, H1 2013
Products under Development for Influenza B Infections – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *